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Abstract
Background: There is still some controversy regarding the ethical issues involved in live donor liver
transplantation (LDLT) and there is uncertainty on the range of perioperative morbidity and mortality risks
that donors will consider acceptable.
Methods: This study analysed donors’ inclinations towards LDLT using decision analysis techniques
based on the probability trade-off (PTO) method. Adult individuals with an emotional or biological
relationship with a patient affected by end-stage liver disease were enrolled. Of 122 potential candidates,
100 were included in this study.
Results: The vast majority of participants (93%) supported LDLT. The most important factor influencing
participants’ decisions was their wish to improve the recipient's chance of living a longer life. Participants
chose to become donors if the recipient was required to wait longer than a mean ± standard deviation (SD)
of 6 ± 5 months for a cadaveric graft, if the mean ± SD probability of survival was at least 46 ± 30% at
1 month and at least 36 ± 29% at 1 year, and if the recipient's life could be prolonged for a mean ± SD
of at least 11 ± 22 months.
Conclusions: Potential donors were risk takers and were willing to donate when given the opportunity.
They accepted significant risks, especially if they had a close emotional relationship with the recipient.
Received 4 July 2013; accepted 19 September 2013
Correspondence
Michele Molinari, Dalhousie University, 1276 South Park Street, Room 6-302, Victoria Building,
Halifax, NS B3H 2Y9, Canada. Tel: + 1 902 473 7624. Fax: + 1 902 473 7639. E-mail: michele.molinari
@cdha.nshealth.ca
Introduction
Liver transplantation (LT) represents the only cure for patients
with end-stage liver disease (ESLD).1 Despite efforts to increase
the number of donors, patients with ESLD still outnumber the
pool of available grafts,2,3 which results in a 7–10% mortality rate
among patients on the waiting list.4,5 The discrepancy between
organ supply and demand has become the biggest challenge for
the transplant community.6 The need for more liver grafts has led
clinicians and policymakers to identify strategies that might help
to close the gap between demand and supply.7–9 The utilization of
grafts from extended criteria donors10,11 has been valuable, but
insufficient to provide an adequate number of organs.8 In more
recent years, a considerable number of transplant programmes
have embraced the use of grafts from patients suffering cardiac
death12,13 and from living donors.14,15
Living donor liver transplantation (LDLT) was pioneered in
children and small adults. To date, more that 12 000 adult LDLTs
have been performed worldwide.16 By promoting LDLT, trans-
plant centres might increase the number of available grafts and
reduce the mortality risk of patients on the waiting list.5 Several
other benefits are unique to LDLT, such as the short cold ischae-
mia time, the anticipated good quality of the grafts and the fact
that transplant surgery can be performed electively.17,18 However,
LDLT is a technically complex procedure19 that absorbs substantial
human and financial resources20 and is ethically controversial
because of the risks to donors.15,21–25 There is still some disagree-
ment regarding the ethics surrounding LDLT26,27 and there is
uncertainty on the range of perioperative morbidity and mortality
risks that living liver donors (LLDs) will consider acceptable.28 To
investigate some of these issues, a prospective study was designed
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to assess potential LLDs’ inclinations towards LDLT and to
measure the strength of their choices. Secondary aims were to
determine the minimal survival benefits to recipients and the
perioperative morbidity and mortality risks that potential LLDs
will consider acceptable before proceeding with donation.
Materials and methods
Study population and settings
During the period between February 2009 and October 2011,
a total of 96 patients with ESLD were referred to the Queen
Elizabeth II Medical Centre (Halifax, NS, Canada) for LT. All of
these patients were eventually listed for a cadaveric LT after they
had been fully assessed. Individuals who were responsible for
patients’ daily care or who were emotionally or biologically related
to the potential recipients were identified and screened for this
study. Of the 122 potential participants, 22 subjects did not
consent to participate. A total of 100 individuals satisfied the
inclusion criteria and were enrolled. Recruitment took place in the
outpatient clinics at a tertiary university centre in which only
cadaveric LTs are currently performed.
Human subject protection
This study was approved by the Queen Elizabeth II Health Sci-
ences Centre Institutional Review Board.
Inclusion and exclusion criteria
Participants were informed that LDLT was not performed at the
study institution but was available in other Canadian university
hospitals. They were provided with a written questionnaire in
order to collect information on their sociodemographic status and
past medical history. Inclusion criteria required each potential
participant to: have a well-established emotional or biological
relationship with a patient referred for LT; to be aged >18 years; to
be fit enough to undergo hepatic resection; to be able to provide
informed consent, and to be numerically literate. A shortened
validated psychometric test29 incorporating numerical computa-
tion questions involving basic principles of arithmetic, such as
addition, subtraction, multiplication, division and the calculation
of percentages, was administered to participants to assess their
numeracy. Participants were excluded if they were unable to pass
the psychometric test, were aged >60 years, were affected by any
major comorbid condition or had an abnormal body mass index
(BMI) defined as a BMI of <20 kg/m2 or >30 kg/m2.30,31 Other
exclusion criteria were a history of previous hepatic resection or
major abdominal surgery, and the presence of a significant visual,
hearing or communication impairment.
Participants’ education
Participants were provided a summary table of the potential risks
associated with LDLT (Table 1) and were given standardized
written and oral information about LDLT. Consent forms and
educational materials were written at a sixth-to-eighth-grade
reading level as recommended by previous studies.32 Prior to each
interview, participants underwent a detailed briefing on the
content of the written educational material. After the oral educa-
tional session, they were asked if they needed any further clarifi-
cation; participants who declined that offer were considered to be
fully informed of the three significant components of the surgical
procedure: (i) the health burden imposed on the donor undergo-
ing hepatic resection; (ii) the possible adverse outcomes and ben-
efits for both the donor and the recipient, and (iii) the likelihood
that these outcomes would occur.
Questionnaires
Standardized socioeconomic and demographic questionnaires
were administered to all participants. Data on the following vari-
ables were collected: age; gender; relationship with the potential
recipient; ethnicity; highest level of education; marital status;
living situation; employment, and annual household income. The
Charlson Self-Administered Comorbidity Questionnaire was also
used to assess donors’ health conditions33 and prescriptions of
medications regularly taken were recorded.
Identification of relevant variables
During the development of the study protocol, a group of expert
hepatobiliary and transplant surgeons was consulted to help iden-
tify relevant variables that might influence donors’ inclinations
towards LDLT. The following variables were selected: the donor’s
risk for mortality and morbidity; the donor’s risk for long-term
complications that might decrease his or her physical capacity; the
financial burden imposed by income losses or expenses that
the donor or his or her family might face before and after LDLT;
the donor’s hospital stay and length of time off work or time out
from social or familial duties, and, finally, the recipient’s expected
survival benefit.
Structured interviews
All interviews were held in a quiet and comfortable location in
which the participant and interviewer were alone in order to
prevent any external pressure that might influence participants’
decisions. The research assistant who administered all the ques-
tionnaires and who carried out the interviews (SD) had been
trained to perform probability trade-off (PTO) interviews34 and
followed a standardized protocol summarized in the following
four stages.
Stage 1: the participant was asked whether he or she was willing
or unwilling to undergo a partial hepatic resection in order to
provide a transplantable graft for a recipient of his or her choice.
Stage 2: the strength of the participant’s decision to donate was
tested by eliciting his or her willingness to donate when the fol-
lowing characteristics were modified: (i) the degree of emotional
or biological closeness between the recipient and the donor; (ii)
the cause of the liver disease responsible for hepatic failure in the
potential recipient; (iii) the likelihood of disease recurrence after
LDLT, and (iv) the age of the recipient.
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Stage 3: the importance of variables identified by experts as
relevant was measured on a 10-point psychometric visual ana-
logue scale (VAS) (0 = not important; 10 = very important).35
Stage 4: a PTO interview was used to evaluate the strength of
the participant’s choices. The PTO technique36 is a formal and
quantitative decision analysis technique that uses standardized
instructions and visual aids. An example of the visual aids used in
this study is represented in Fig. 1.37–39
Probability trade-off interviews and their rationale
The rationale for using PTO techniques was based on theoretical
and practical considerations. Probability trade-off has been shown
to capture the complexities of clinical decisions that are made
under conditions of uncertainty and has demonstrated high coef-
ficients of test–retest reliability (0.78–0.94).40,41 The method is able
to determine how strongly individuals adhere to their treatment
preferences34,39 and allows an assessment of potential donor
Table 1 Summary of risks and benefits of living donor liver transplantation (LDLT) extracted from scientific articles published in English during
the last decades
Category LDLT variables Value Reference
Donors’ satisfaction Donors who were satisfied with their decision 74–100% 83,89
Donors who would donate again 73–100% 73,74,83,89,116
Donors who would encourage others to donate 81–92% 73,83
Donors’ risks Donors who developed at least one perioperative complication 30–50% 15,58,73,104,107,117–120
Donors who developed multiple complications after surgery 19–21% 15,104
Donors who developed postoperative life-threatening complications 12–35% 23
Donors who developed major complications that required reoperation 1.5–4.5% 15,104,117,121
Donors who developed bile leaks requiring interventions such as
percutaneous drainage or endoscopic bile duct stenting
4–9% 15
Donors who developed wound infections 20% 15
Donors who developed postoperative urinary infections 10% 15
Donors who developed incisional hernias 5–20% 15,122
Donors who developed postoperative liver failure requiring liver
transplantation
0.20% 123
Donors who experienced postoperative depression that resolved 2–14% 116,117,122,124
Donors’ risk of death Risk of death for donors as a result of surgical complications 0.1–0.5% 15,62,102,123,125
Donors’ operation Donors in whom an incision was made but who were unable to donate
because of an unexpected finding during the operation
2–4.9% 15,103,119,126
Donors who needed at least one unit of blood transfused during or after
surgery
1–4.9% 107,121,127
Mean donor blood loss during surgery 500–750 ml 107
Donors’ recovery Mean hospital stay for the donor after surgery 6–7 days 73,120–122,127
Time necessary for donors to recover completely from surgery 2–14 weeks 73,116
Donors’ long-term
sequelae
Donors who experienced at least one complication after 1 year from donation 7% 15
Donors who needed to be readmitted to hospital after being discharged
home
7–11% 121,122
Donors who needed to change their job as a consequence of their surgery 0% 73
Donors who encountered financial expenses not fully covered by their
insurance
50% 116
Recipients’ benefit Recipients alive at 1 year after LDLT 81–94% 61,93,106
10%
90%
Desired outcome
Undesired outcome
Figure 1 A pie chart used as a visual aid to illustrate to participants
in this study the likelihood of expected outcomes in living donor liver
transplantation
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thresholds for donor morbidity and mortality, and recipient
survival.42–44 In essence, the participant would declare whether he
or she was willing or unwilling to donate after being fully
informed of the expected outcomes of LDLT. Then the interviewer
would increase or decrease the probability of a variable (e.g. donor
morbidity) until the participant changed his or her mind
(Fig. 2).34,36,39,45,46 The difference between the expected probability
quoted at the beginning of the interview and the probability of the
event that would make the participant change his or her mind was
measured. The difference between the two probabilities repre-
sented a measure of the strength of the participant’s preferences.
Sample size
The sample size required to elicit participants’ preferences using
PTO interviews was calculated. Previous studies have shown that
on average 20–30 participants are necessary to explore all the
important aspects of the research question and to achieve theo-
retical saturation.47,48 Theoretical saturation is the point at which
the results of elicitations become repetitive or when no new
themes emerge, and the incremental improvement to the theory is
minimal.49 Estimations for this study indicated that 100 consecu-
tive participants would lead to theoretical saturation and would
allow an exploration of the hypothesis that donor preferences are
associated with an emotional, socioeconomic or familial relation-
ship between the participant and recipient, the recipient’s age, the
cause of liver failure and the risk for recurrent disease.
Statistical analysis
Descriptive data were reported using estimates of central ten-
dency (means, medians) and spread [standard deviations (SDs),
ranges] for continuous data and frequencies and percentages for
categorical data. Comparisons between groups were made using
cross-tabulation with the appropriate test statistics (Pearson’s
chi-squared test or Fisher’s exact test as appropriate) for categori-
cal variables and the Wilcoxon test for non-normally distributed
continuous data. spss Statistics for Windows Version 19.0 (IBM
Corp., Armonk, NY, USA) was used for all statistical analyses. All
reported P-values are two-sided. P-values of <0.05 are considered
to indicate statistical significance.
Results
Baseline participant characteristics
The demographic and socioeconomic characteristics of partici-
pants are summarized in Table 2. Demographic characteristics
reflected the demographic and socioeconomic statuses of resi-
dents of the Canadian provinces of Nova Scotia, Prince Edward
Island, Newfoundland and Labrador, and New Brunswick.50 The
majority of patients who were referred for LT suffered from cir-
rhosis secondary to alcoholism (32%) or infection with hepatitis
C virus (HCV) (18%) (Table 3).51,52
Participants’ willingness to donate
A total of 93% of participants chose to become donors (P =
0.0001) (Fig. 3). No statistically significant difference was noted
between the two genders (P = 0.72). The limited number of par-
ticipants who were ambivalent or refused donation did not allow
any investigation of possible prognostic factors associated with a
negative response towards living donation.
Biological and social relationship with the recipient
The intimacy of the relationship between the participant and
patient played an important role in participants’ decisions. As the
biological or social relationship between the donor and recipient
pair was modified to a more distant association, participants
became less inclined to donate (Fig. 4) (P = 0.0001).
Recipient characteristics and cause of liver disease
Participants’ decisions on donation also depended on additional
factors such as the aetiology of the recipient’s liver failure, the recip-
ient’s age and the probability that liver failure would reoccur after
LT (P = 0.0001) (Fig. 5). Even when the aetiology of ESLD was
self-inflicted, such as in alcoholic cirrhosis, 81% of participants
were keen to donate if surgery could prolong the recipient’s sur-
vival. However, their decision was conditional on the existing
conduct of the recipient as only 20% were willing to undergo
surgery if the recipient continued to indulge in the behaviour that
had caused liver failure. Participants were largely willing to donate
Initial perioperative mortality risk Incremental perioperative mortality risk 
Perioperative
mortality risk, %
Minimal perioperative
mortality risk increment 
to make the participant
change his or her mind 
When perioperative mortality risk  
reached 15%, the participant changed 
his or her mind and refused to become a live liver 
donor. This value becomes the threshold for that 
specific participant 
When presented with a mortality 
risk of 5%, the participant chose to 
become a live liver donor 
Figure 2 Representation of how probability trade-off technique
works. The participant was given an initial scenario (left-hand bar) in
which the risk for perioperative mortality following living donor liver
transplantation was 5%. During the interview, the risk for
perioperative mortality was increased by increments of 1% until it
reached 15% (right-hand bar). At this level of risk, the participant
changed his or her mind and declined to become a live liver donor.
In this example, this participant's threshold for perioperative mortal-
ity risk was 15% and the maximum risk increment tolerable (thresh-
old value minus initial value) was 10%
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(75%) even when the primary disease responsible for liver failure
was likely to reoccur, such as in HCV-positive recipients, and 88% of
participants were willing to donate to individuals aged >65 years.
Importance of selected variables
Figure 6 represents the levels of importance attributed by partici-
pants to the variables identified as influential by experts. The most
dominant variable was the recipient’s potential life gain, followed
by the donor’s morbidity, mortality and loss of his or her own
physical capacity. Factors such as the donor’s time off work, the
length of the donor’s hospital stay, the financial burden to the
donor, and the aetiology of the liver disease were considered less
important (P = 0.001). No statistically significant differences were
noted between participants who were self-employed and those
Table 2 Participants’ characteristics (n = 100)
Variable Values
Age, years, mean ± SD 47.8 ± 12.4
Gender, female, n 70
Social or familial relationship of participant to recipient, n
Child 18
Sibling 11
Spouse/partner 42
Parent 4
Niece/nephew 2
Other 23
Participants’ ethnicity, n
African-Canadian 4
First Nation 5
White 91
Participants’ highest level of education, n
University 33
College 35
High school 31
Elementary school 1
Participants’ social status, n
Common law 15
Married 63
Single (widow) 4
Single (divorced or separated) 6
Single (never married) 12
Composition of participant's household, n
Alone 5
Spouse/partner 77
Parents 2
Child/children 6
Friends 7
Others 3
Subject's current employment status, n
Home-maker 5
Unemployed 6
On disability 7
Employed 68
Retired 12
Student 2
Variable Values
Subject's current work status, n
Part-time 24
Full-time 76
Participants’ employment status, n
Employed by others 85
Self-employed 15
Participants’ average number of work hours per week, n
0–20 4
21–40 41
>41 25
Participants’ household overall income per year (2010), n
<Can$50 000 41
Can$50 000–100 000 42
Can$100 001–150 000 8
>Can$150 000 6
Participant's average income per year (2010), n
<Can$50 000 68
Can$50 000–100 000 24
Can$100 001–150 000 5
>Can$150 000 3
Households financially dependent on participant, n
Yes 87
No 13
Individuals financially supported by the subject at the time of the
interview, n
4 3
3 9
2 22
1 38
0 28
People dependent on participant for care, n
4 3
3 7
2 16
1 36
0 38
SD, standard deviation.
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who worked in other capacities, or according to the gender or age
of participants.
Risk and benefit thresholds
All participants who expressed the desire to donate underwent
PTO interviews to measure the strength of their decisions.
Ambivalent participants and subjects who said they would refuse
to donate were excluded as they were a group too small to provide
any meaningful information for the scope of this study. Thresh-
olds of relevant variables were grouped in three categories. The
first category related to the perioperative risks and financial
burdens experienced by the participant. The second category con-
cerned the time the recipient would spend on the waiting list for
a cadaveric graft and the benefits that he or she would obtain from
LDLT. The last category related to the surgical expertise of the
transplant team. The mean, range and SD values of the thresholds
are summarized in Table 4.
Risk and benefit curves
Curves showing cumulative percentages indicating participants’
preferences are reported in Fig. 7(a–g). These curves represent
participants’ choices under different circumstances and were cal-
culated by varying the potential risks and benefits of LDLT.
Figure 7a represents participants’ inclinations to donate accord-
ing to the potential risks of surgery. Half (50%) of participants
declined surgery when the risk for complications was ≥75%
[interquartile range (IQR): 25–100%] and the risk for death was
≥30% (IQR: 10–50%). Half (50%) of participants refused surgery
when the expected time necessary for their recovery was ≥24
weeks (IQR: 8–30 weeks) and the median quantity of transfusion
required amounted to ≥3 units of packed red blood cells (IQR:
2–6 units) (Fig. 7b, c). Half (50%) of participants declined LDLT
when the recipient’s median time on the waiting list for a
cadaveric LT was ≤3 months (IQR: 3–6 months), when the median
survival benefit to the recipient was ≤6 months (IQR: 1–12
months) and when the median age of the recipient was ≥75 years
(IQR: 70–80 years) (Fig. 7d–f). With regard to the technical
experience of the surgical team, 50% of participants felt they
would feel comfortable about donating only when transplant sur-
geons had already performed at least 10 LDLTs (IQR: 5–25 LDLTs)
(Fig. 7g).
Discussion
Over the last decades, outcomes of patients receiving LDLTs have
improved to the point that53 they are now comparable to
cadaveric grafts.54–61 The small but not negligible risks to donors
make LDLT controversial from a purely ethical point of view.21,60,62
Previous studies have addressed how members of society,26,63–69
health care providers27,66,68,70,71 and patients on the waiting list72
feel about LDLT. A handful of studies have examined how living
donors felt about LDLT after they had undergone surgery.48,55,73–75
Although listening to the voices of donors is paramount, recall
bias played a role in donors’ responses in these studies because
their decisions had already been made and they had survived
surgery.76 It is not surprising that the vast majority of the donors
recruited in these studies supported LDLT because their dona-
tions may have saved family members or friends.77–80 In reality,
however, choices must be made in the face of uncertainty and
the risks for undesirable events must be carefully weighted.81
The ethical dimension of equipoise mandates that the risk to the
donor must balance the benefit to the recipient,82 but it is
still unclear who should make the ultimate decision in support
or rejection of the practice of LDLT. Because no previous
studies have investigated donors’ preferences prior to undergoing
surgery, the present authors recruited a pool of potential donors
and elicited their inclinations and measured the strength of their
decisions.34,39–44
The primary result of the present study showed that the major-
ity of participants desired to become donors. Contrary to other
studies, in which ambivalent feelings towards LDLT were mea-
sured in 20–65% of subjects,67,83–85 only 5% of participants were
ambivalent and 2% declined surgery. The percentage of partici-
pants in the present study who were ambivalent about or opposed
to becoming donors is considerably lower than the ranges previ-
ously described by others.67,83–85 This may reflect the fact that,
although participants satisfied the criteria required of a donor,
they knew that opportunities to donate were not available at the
study transplant centre, although they were informed that these
were available in other Canadian transplant centres. Because the
study institution did not offer any opportunity to participate in
LDLT, study subjects may have felt that their decisions did not
have any tangible implications and carried no real risks to their
health. Another possible explanation is that the vast majority of
participants were spouses, children and siblings of patients in
need of an LT. These participants may have been more motivated
than other groups because of the strength of their emotional
relationships with the potential recipients or because they felt
guilty about or accountable for recipients’ conditions.86,87 When
participants were asked for the rationale for their decision to
donate, the desire to prolong the recipient’s life emerged as the
Table 3 Primary aetiology of liver failure in 96 patients referred for
liver transplantation
Aetiology of liver failure %
Alcohol-induced cirrhosis 33%
Viral hepatitis C 18%
Primary biliary cirrhosis 10%
Other causes 9%
Non-alcoholic steatohepatitis (NASH) 8%
Primary sclerosing cholangitis 8%
Autoimmune hepatitis 8%
Acute liver failure 5%
Viral hepatitis B 2%
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main motive, even if the benefits to the recipient were moderate.88
The donor–recipient relationship played an important role
because the percentage of participants willing to donate declined
when the relationship with the recipient became more distant.46 In
general, potential donors were ready to make a great deal of self-
sacrifice as they put the benefits to the recipient far ahead of their
own risks.86,87 Participants were willing to donate even when the
potential recipient was elderly or affected by liver failure that
might reoccur. They also had high thresholds for changing their
minds when they were told that surgery might imply the need for
several blood transfusions, the need to take considerable time off
work, a long period of convalescence, relatively high financial
burdens and, above all, high morbidity and mortality. In a manner
similar to that observed by Papachristou et al.,48 the present study
subjects also gave the impression that they desired to keep the
recipient alive at any cost, without fully appreciating the very high
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Figure 3 Preferences of participants asked if they were willing to undergo partial hepatectomy to donate part of their liver to a potential
recipient waiting for a liver transplant (P = 0.0001)
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Figure 4 Percentages of participants willing to donate part of their liver in living donor liver transplantation based on the recipient–donor
relationship (P = 0.0001)
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Figure 5 Percentages of participants willing to donate part of their liver in living donor liver transplantation based on the primary cause of
the liver disease affecting the recipient, the probability that liver failure might reoccur because of the nature of the original disease or
self-inflicted hepatotoxicity and the age of the recipient (P = 0.001). HCV, hepatitis C virus; PSC, primary sclerosing cholangitis
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Figure 6 Importance attributed to some of the variables influencing participant decisions. Values were measured using a visual analogue
scale (VAS; 0 = non-important, 10 = extremely important) in 93 participants who were willing to donate. The number of participants who were
ambivalent or against donation was too small to allow any meaningful analysis. Error bars show 95% confidence intervals
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personal risks inherent in the fulfilling of this wish. However,
donors’ willingness to donate was not unconditional because no
donors were willing to take part in donation to a stranger and the
rate of willingness to donate decreased when the potential recipi-
ent continued to harm his or her liver or was elderly.
Strengths of this study
The present study has several strengths. To the present authors’
knowledge, this is the first investigation designed to measure risk
thresholds in potential donors in a prospective and systematic
way. Participants were selected only if they satisfied very stringent
inclusion criteria that were comparable with the criteria used by
most transplant centres when selecting potential LLDs. This strat-
egy represented an attempt to control for some of the socioeco-
nomic and emotional characteristics that might influence decision
making and preferences. In addition, the fact that participants
were not able to donate because LDLT was not offered at the study
centre was in some ways advantageous because participants’ deci-
sions were not subject to the psychological or emotional pressure88
that occurs when donors are evaluated for LDLT in centres at
which this procedure is performed. Another of the most impor-
tant aspects of the present study was that participants were fully
informed about the risks and benefits associated with LDLT.89 This
required the input of a dedicated person and took several hours
and therefore is not feasible in most busy clinical settings. Because
the present study adhered to a well-defined study protocol, the
authors are confident that all possible measures were taken to
make participants very well informed and that there are no other
significant measures that could have improved the quality of par-
ticipants’ education on LDLT. Other strong points of this study
include the method (PTO) used to elicit preferences in a system-
atic and impartial way.
Limitations of this study
This study has several shortcomings. In the majority of decision
analysis models, it is assumed that individuals make decisions
based only on rational thinking.90 This may not be true in health
care as several studies have shown that decision making can
be led by emotions more than it is by a lucid cognitive
process,90–92 and that decisions are influenced by cultural and
social characteristics.48,73,74,93 Unlike members of the transplant
team, who have experience with the complications of the pro-
cedure, potential donors have a more superficial understanding
based on descriptions of the probabilities of events. Volk et al.94
speculated that donors may assume that LDLT will benefit the
recipient because it is being offered by the medical community,
as other authors have indicated,95,96 and many donors appear
to make decisions even before they know the risks of the
operation.48,75,84,91,93,94,97
Another important limitation concerned the possibility that
potential donors might not have fully understood the risks asso-
ciated with donation27,56,93 as the thresholds for the risks for mor-
bidity and mortality in this study were outside the range
considered sensible by any health care provider. Although the
present study was carried out following a standardized interview
process and the numerical literacy of all participants was tested,
participant preferences were measured only once. Therefore it is
reasonable to think that their opinions might change over time98,99
and that donors might later be unwilling to accept that level of
risk as it is well known that some LDLT donors change their
Table 4 Probability trade-off values for participants’ decision making
Variable Minimum Maximum Mean SD
Donors’ burden Risk of perioperative complications that would make participants decline to donate 0.5 100 64.2 35.9
Risk of perioperative mortality that would make participants decline to donate 0.1 100 40.4 33.6
Weeks required to make a complete recovery after partial hepatectomy that would
make participants decline to donate
2 104 26.7 23.7
Financial burden that would make participants decline to donate, Can$, year 2010 500 5000 1868 1762
Number of transfusions of packed red blood cells that would make participants
decline to donate
1 10 4.3 2.9
Recipient
characteristics
Months spent by the recipient on the cadaveric organ waiting list that would make
participants decide to donate
0 24 6.0 5.8
Recipient's survival probability at 1 month that would make participants decide to
donate
0 100 46.1 30.4
Recipient's survival probability at 1 year that would make participants decide to
donate
0 98 35.9 29.5
Months of life gained by recipient that would make participants decide to donate 0 156 11.4 22.1
Maximum recipient age that would make participants decline donation, years 40 100 74.6 9.9
Transplant team
experience
Minimum number of living related liver surgeries already performed by the surgical
transplant team that would make participants feel comfortable about donating
0 140 14.2 20.6
SD, standard deviation.
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commitment just before their operation. Therefore, further
research should clarify the actual risk thresholds of donors closer
to the time of surgery to allow for the meaningful generalization
of the present findings.
Clinical implications
The results of this study may have several practical implications
because individuals who have an emotional attachment to
someone who is suffering from ESLD are very interested in LDLT.
Therefore, LDLT should be openly discussed with patients and
their families and friends as the human cost of an insufficient
supply of cadaveric grafts remains high.4,100 During the last
decade, the number of adult LDLTs performed in North America
has declined. This may reflect the occurrence of a donor death in
New York in 2002, but it may also reflect the introduction of the
Model for End-stage Liver Disease (MELD) scoring system, which
gives patients with hepatocellular carcinoma, formerly the most
common recipients of LDLTs, priority in the use of cadaveric
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livers.59,101–104 The combination of these factors may explain why
LDLTs currently account for <5% of all LTs in the USA.105,106
Live donor morbidity and mortality are inevitable,107 but nowa-
days the mortality risk is estimated to be as low as 0.2–0.5%108,109
and 5-year recipient survival exceeds 70%.85 In comparison, par-
ticipants in the present study indicated they would accept a 70%
risk for morbidity, a 30% risk for mortality, and a recipient life
gain of only 6 months. This disparity between the actual risks
reported in the literature and those considered acceptable by par-
ticipants in the present study brings to attention two key issues.
Firstly, the risks of LDLT are currently lower than the risks donors
are willing to accept and, secondly, donors are willing to accept a
greater level of risk than are clinicians.27
Because of the discrepancy between the views of clinicians and
potential donors, health care providers should recognize that they
should not make decisions on LDLTs alone. The information that
LDLT can save selected patients with ESLD or hepatocellular car-
cinoma should be shared with patients and their families and
friends, although the procedure carries some risks that cannot be
minimized.88 The present authors believe that shared decision
making satisfies all of the parties involved88,110–114 and that, regard-
less of recipient outcomes, there are benefits to be derived by
potential donors from their active involvement in some of the
decision making that can reduce their anxiety and regret about
being unable to help a loved person in need.115 Nevertheless, the
present authors share the concerns raised by Malago et al.62 over
the fact that, since 1998, the potential benefits of LDLT have
encouraged the rapid and uncoordinated worldwide development
of programmes offering the procedure. Therefore, health profes-
sionals should maintain a central role in guiding, informing,
counselling and warning all parties of the risks and benefits asso-
ciated with LDLT. This is to guarantee that the right of healthy
individuals to make choices regarding the act of donation89 is
fulfilled only in centres that have demonstrated excellent out-
comes and have the necessary resources.62
Conclusions
The present study offers a snapshot of the opinions of potential
LLDs on LDLT and the risks that come with this procedure. The
study findings indicate that potential donors are risk takers and
that 93% of subjects appeared to be interested in donating. The
most important reason for donating is to keep a loved person
alive, especially if there is a very close emotional relationship
between the recipient and donor, even in the presence of signifi-
cant risk for perioperative morbidity and mortality.
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